These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 29534896)

  • 41. Cystathionine as a marker for 1p/19q codeleted gliomas by in vivo magnetic resonance spectroscopy.
    Branzoli F; Pontoizeau C; Tchara L; Di Stefano AL; Kamoun A; Deelchand DK; Valabrègue R; Lehéricy S; Sanson M; Ottolenghi C; Marjańska M
    Neuro Oncol; 2019 Jun; 21(6):765-774. PubMed ID: 30726924
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Mitotic index, microvascular proliferation, and necrosis define 3 pathological subgroups of prognostic relevance among 1p/19q co-deleted anaplastic oligodendrogliomas.
    Figarella-Branger D; Mokhtari K; Dehais C; Carpentier C; Colin C; Jouvet A; Uro-Coste E; Forest F; Maurage CA; Vignaud JM; Polivka M; Lechapt-Zalcman E; Eimer S; Viennet G; Quintin-Roué I; Aubriot-Lorton MH; Diebold MD; Loussouarn D; Lacroix C; Rigau V; Laquerrière A; Vandenbos F; Michalak S; Sevestre H; Peoch M; Labrousse F; Christov C; Kemeny JL; Chenard MP; Chiforeanu D; Ducray F; Idbaih A; Delattre JY;
    Neuro Oncol; 2016 Jun; 18(6):888-90. PubMed ID: 27175000
    [No Abstract]   [Full Text] [Related]  

  • 43. Pilot evaluation of 1p and 19q deletions in anaplastic oligodendrogliomas collected by a national cooperative cancer treatment group.
    Jenkins RB; Curran W; Scott CB; Cairncross G
    Am J Clin Oncol; 2001 Oct; 24(5):506-8. PubMed ID: 11586105
    [TBL] [Abstract][Full Text] [Related]  

  • 44. New clinical, pathological and molecular prognostic models and calculators in patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951.
    Gorlia T; Delattre JY; Brandes AA; Kros JM; Taphoorn MJ; Kouwenhoven MC; Bernsen HJ; Frénay M; Tijssen CC; Lacombe D; van den Bent MJ
    Eur J Cancer; 2013 Nov; 49(16):3477-85. PubMed ID: 23896377
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Integrated analysis identified genes associated with a favorable prognosis in oligodendrogliomas.
    Liu Y; Hu H; Zhang C; Wang Z; Li M; Jiang T
    Genes Chromosomes Cancer; 2016 Feb; 55(2):169-76. PubMed ID: 26542540
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prognostic significance of relative 1p/19q codeletion in oligodendroglial tumors.
    Chamberlain MC; Born D
    J Neurooncol; 2015 Nov; 125(2):249-51. PubMed ID: 26341371
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Application of brush cytology for FISH-based detection of 1p/19q codeletion in oligodendroglial tumors.
    Srebotnik-Kirbiš I; Limbäck-Stokin C
    J Neurooncol; 2016 Sep; 129(3):415-422. PubMed ID: 27406587
    [TBL] [Abstract][Full Text] [Related]  

  • 48. p-CREB expression in human gliomas: potential use in the differential diagnosis between astrocytoma and oligodendroglioma.
    Barresi V; Mondello S; Branca G; Rajan TS; Vitarelli E; Tuccari G
    Hum Pathol; 2015 Feb; 46(2):231-8. PubMed ID: 25476123
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402.
    ; Cairncross G; Berkey B; Shaw E; Jenkins R; Scheithauer B; Brachman D; Buckner J; Fink K; Souhami L; Laperierre N; Mehta M; Curran W
    J Clin Oncol; 2006 Jun; 24(18):2707-14. PubMed ID: 16782910
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402.
    Cairncross G; Wang M; Shaw E; Jenkins R; Brachman D; Buckner J; Fink K; Souhami L; Laperriere N; Curran W; Mehta M
    J Clin Oncol; 2013 Jan; 31(3):337-43. PubMed ID: 23071247
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Assessment of 1p/19q status by fluorescence in situ hybridization assay: A comparative study in oligodendroglial, mixed oligoastrocytic and astrocytic tumors.
    Shukla B; Agarwal S; Suri V; Pathak P; Sharma MC; Gupta D; Sharma BS; Suri A; Halder A; Sarkar C
    Neurol India; 2009; 57(5):559-66. PubMed ID: 19934553
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Molecular analysis of chromosome 1, 10 and 19 abnormalities in human oligodendroglial tumors: relationship between frequency of LOH grade, age and gender.
    Gresner SM; Rieske P; Wozniak K; Piaskowski S; Jaskolski DJ; Skowronski W; Golanska E; Sikorska B; Liberski PP
    Clin Neuropathol; 2006; 25(1):18-24. PubMed ID: 16465770
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The impact of molecular and clinical factors on patient outcome in oligodendroglioma from 20 years' experience at a single centre.
    Parkinson JF; Afaghi V; Payne CA; Buckland ME; Brewer JM; Biggs MT; Little NS; Wheeler HR; Cook RJ; McDonald KL
    J Clin Neurosci; 2011 Mar; 18(3):329-33. PubMed ID: 21247767
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Molecular imaging of 1p/19q deletion in oligodendroglial tumours with 11C-methionine positron emission tomography.
    Iwadate Y; Shinozaki N; Matsutani T; Uchino Y; Saeki N
    J Neurol Neurosurg Psychiatry; 2016 Sep; 87(9):1016-21. PubMed ID: 26848169
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Is the 1p/19q deletion a diagnostic marker of oligodendrogliomas?
    Gadji M; Fortin D; Tsanaclis AM; Drouin R
    Cancer Genet Cytogenet; 2009 Oct; 194(1):12-22. PubMed ID: 19737649
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Imaging growth as a predictor of grade of malignancy and aggressiveness of IDH-mutant and 1p/19q-codeleted oligodendrogliomas in adults.
    Roux A; Tauziede-Espariat A; Zanello M; Peeters S; Zah-Bi G; Parraga E; Edjlali M; Lechapt E; Shor N; Bellu L; Berzero G; Dormont D; Dezamis E; Chretien F; Oppenheim C; Sanson M; Varlet P; Capelle L; Dhermain F; Pallud J
    Neuro Oncol; 2020 Jul; 22(7):993-1005. PubMed ID: 32025725
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Oligodendrogliomas: new insights from the genetics and perspectives.
    Alentorn A; Sanson M; Idbaih A
    Curr Opin Oncol; 2012 Nov; 24(6):687-93. PubMed ID: 22913971
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Contribution of 1p, 19q, 9p and 10q Automated Analysis by FISH to the Diagnosis and Prognosis of Oligodendroglial Tumors According to WHO 2016 Guidelines.
    Michaud K; de Tayrac M; D'Astous M; Duval C; Paquet C; Samassekou O; Gould PV; Saikali S
    PLoS One; 2016; 11(12):e0168728. PubMed ID: 28030632
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Predictors and early survival outcomes of maximal resection in WHO grade II 1p/19q-codeleted oligodendrogliomas.
    Harary M; Kavouridis VK; Torre M; Zaidi HA; Chukwueke UN; Reardon DA; Smith TR; Iorgulescu JB
    Neuro Oncol; 2020 Mar; 22(3):369-380. PubMed ID: 31538193
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Gliosarcoma arising in oligodendroglial tumors ("oligosarcoma"): a clinicopathologic study.
    Rodriguez FJ; Scheithauer BW; Jenkins R; Burger PC; Rudzinskiy P; Vlodavsky E; Schooley A; Landolfi J
    Am J Surg Pathol; 2007 Mar; 31(3):351-62. PubMed ID: 17325476
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.